slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 73,771-73,800
Pages 3,679
Rows per page 30
Component
73,771-73,800 of 110,355
08
The slide highlights the structural difference of the NXC-201 molecule compared to Abecma, Carvykti, and CART-ddBCMA.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
12
The slide uses a process flow diagram to illustrate the disease mechanism and a human anatomy diagram to show clinical manifestations.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
16
Includes a footer citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
17
Includes detailed clinical trial references in the footer.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
20
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
21
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
22
The slide uses a wave-like visual to represent market size, with specific dollar amounts associated with different disease categories.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
31
The slide uses a step-wise process diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
33
Includes scientific diagrams of molecular pathways and efficacy data charts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
39
The slide uses a bubble chart to map clinical trials and a table to summarize drug performance metrics, highlighting low efficacy and high toxicity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
43
The slide uses a process-flow layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
45
Includes technical diagrams of the drug delivery mechanism and comparative survival data.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
46
Includes two sets of charts: tumor volume over time and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
47
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
54
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
56
The slide uses a bar chart to contrast the combined annual sales of two sets of oncology drugs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
08
The slide uses two donut charts to visualize the composition of the loan portfolio, with a note clarifying the total portfolio value and the split between C&I and investment real estate.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
14
The slide uses a combination of a donut chart for composition and a combo bar-line chart for trends.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Satisfaction1 hit
15
The slide uses a stacked bar chart for expenses and a bar chart for the efficiency ratio to illustrate cost management.Independent Bank Corp | Results Presentation Deck | 27 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Satisfaction1 hit